Edwards Lifesciences Q2 2023 Earnings Report
Key Takeaways
Edwards Lifesciences reported an 11% increase in sales to $1.53 billion in Q2 2023, with all product groups achieving double-digit constant currency sales growth. Adjusted EPS was $0.66. The company has increased its full-year outlook due to strong first-half performance and improved healthcare staffing.
Q2 sales grew 11 percent to $1.53 billion; constant currency sales grew 12 percent.
All product groups achieved double digit constant currency sales growth in Q2.
Q2 TAVR sales grew 9 percent; constant currency sales grew 10 percent.
Q2 EPS of $0.50 (includes charge from previous IP agreement); adjusted EPS of $0.66.
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Forward Guidance
Edwards Lifesciences expects full year 2023 sales to be in the $5.9 to $6.1 billion range and adjusted earnings per share to be $2.50 to $2.60. For the third quarter of 2023, the company projects total sales to be between $1.44 and $1.52 billion, and adjusted EPS of $0.55 to $0.61.
Positive Outlook
- Full year 2023 sales to be in the $5.9 to $6.1 billion range.
- Full-year total company and TAVR sales growth to be in the 10 to 13 percent range on a constant currency basis.
- TAVR sales of $3.85 to $4.0 billion.
- TMTT sales of $180 to $200 million.
- Surgical Structural Heart sales of $960 million to $1.02 billion.
Challenges Ahead
- For the third quarter of 2023, the company projects total sales to be between $1.44 and $1.52 billion.
- Adjusted EPS of $0.55 to $0.61 for the third quarter of 2023.
- The company's forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.
- Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements.
- Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include risk and uncertainties associated with the COVID pandemic, clinical trial or commercial results or new product approvals and therapy adoption.
Revenue & Expenses
Visualization of income flow from segment revenue to net income